Nurix Therapeutics, Inc.
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All NRIX news ›Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?
Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3…
NurExone Biologic Inc. (NRX.V)
Stock Price, News, Quote & History Yahoo! Finance Canada Oops, something went wrong NurExone Biologic Inc. (NRX.V) NurExone Biologic Inc. Overview Biotechnology / Healthcare NurExone Biologic Inc., a pharmaceutical technology company,…
Nurix Therapeutics Enrolls First Patient in Phase 1b/2 Study of Bexobrutideg Combined with Venetoclax in CLL
Nurix Therapeutics has enrolled the first patient in a study combining bexobrutideg with venetoclax for CLL treatment. Bexobrutideg is an investigational oral Bruton’s tyrosine kinase (BTK) degrader being developed for B-cell malignancies.…
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
ZIM Raises Full-Year 2026 Guidance The combination program could extend beyond previously treated CLL to first-line treatment and other B-cell malignancies. Nurix Therapeutics (Nasdaq: NRIX) enrolled the first patient in its Phase 1b/2…
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage
Posted by Danessa Lincoln on Oct 8th, 2026 Addex Therapeutics Ltd. (NASDAQ: ADXN) said Neurosterix completed Phase 1 studies of NTX-253 and plans to move the drug into Phase 2. NTX-253 is a positive allosteric modulator of the muscarinic…
REGENXBIO (NASDAQ:RGNX) Upgraded at Mizuho
Posted by Mitch Edgeman on Oct 8th, 2026 Mizuho upgraded shares of REGENXBIO (NASDAQ:RGNX – Free Report) to a strong-buy rating in a research note released on Monday,Zacks reports. View Our Latest Research Report on RGNX Stifel Nicolaus…
Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
Roche is paying up to $1.27bn to gain the global rights to Alector's Parkinson's disease candidate, giving the drugmaker access to a drug that aims to overcome delivery limitations that have plagued the disease space in recent years.…
Alector surges on licensing agreement with Genentech
Alector stock jumps 22% after Genentech/Roche licenses AL050 for Parkinson’s. Read more here. Just_Super/iStock via Getty Images - Alector (ALEC) is up ~22% in Monday morning trading after announcing a licensing deal for its AL050 program…
Waldenstrom Macroglobulinemia Market 2026-2036: BTK Degraders, BCL-2 Inhibitors, and Radiotherapeutics Build Momentum Beyond BTK Inhibitors | Thelansis
Waldenstrom Macroglobulinemia Market 2026-2036: BTK openPR.com Waldenstrom Macroglobulinemia Market 2026-2036: BTK Degraders, BCL-2 Inhibitors, and Radiotherapeutics Build Momentum Beyond BTK Inhibitors | Thelansis Press release from:…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
themarketsdaily.com5
-
finance.yahoo.com4
-
european-biotechnology.com3
-
seekingalpha.com3
-
biospace.com2
Measured across the 4Townhouses news index. Headline tone is a simple word-based reading of the latest 58 headlines, not a forecast.